Program & Schedule

Special Interest Icons

Sessions marked with these icons are designated as of special interest or value to these attendees:

Early Career -- Early Career     Primary Care -- Primary Care    

Click here for details

  • Tuesday, April 8, 2014


    3:00 pm – 5:00 pm

    Finance Committee Meeting

    Ruby Lake, Lobby Level


    6:00 pm – 9:00 pm

    Board of Directors Meeting

    Lake Florence, Lobby Level

  • Wednesday, April 9, 2014


    7:30 am – 9:00 am

    Corporate Roundtable Breakfast

    Lake Highland, Lobby Level


    8:00 am – 6:00 pm

    Board of Directors Meeting

    Lake Mizell, Lobby Level


    5:00 pm – 8:00 pm

    Registration Open

    Orlando Ballroom Foyer, Lower Level


    6:00 pm – 7:30 pm

    Fundamentals Planning Committee Meeting

    Lake Lucerne, Lobby Level


    10:00 pm – 11:00 pm

    Mutual Help Meeting

    Lake Lucerne, Lobby Level

    Held each morning and evening of the conference, these peer-run addiction problem-specific support group meetings are open to any participant.


  • Thursday, April 10, 2014


    7:00 am – 8:00 am

    Mutual Help Meeting

    Lake Lucerne, Lobby Level


    7:00 am – 8:00 pm

    Registration Open

    Orlando Ballroom Foyer, Lower Level


    7:00 am – 8:00 am

    Nomination and Awards Committee Meeting

    Lake Florence B, Lobby Level


    8:00 am – 5:30 pm

    Pre-Conference Course

    The ASAM Fundamentals of Addiction Medicine—A Live Course

    (Separate Registration Fee) *

    Commercial Support
    Alkermes provided an unrestricted educational grant to assist with the delivery of this live course.

    * This highly interactive session will not be recorded and will not be available online through ASAM's e-LLC after the conference.

    Orange Ballroom AB, Lower Level



    Pre-Conference Course

    Pain & Addiction Course: Common Threads XV—The Agony and the Partial Agonist

    (Separate Registration Fee)

    Orlando Ballroom IV-V, Lower Level



    Pre-Conference Course

    The New ASAM Criteria and Software Course—What’s New and How to Use the Criteria

    (Separate Registration Fee)

    Orange Ballroom C, Lower Level


    3:45 pm – 4:45 pm

    ASAM Chapter Development Meeting

    Lake Concord, Lobby Level


    5:00 pm – 6:00 pm

    New Member Welcome Reception

    Lake George A, Lobby Level


    5:00 pm – 7:00 pm

    Publications Council Meeting

    Lake Florence B, Lobby Level


    5:00 pm – 6:00 pm



    5:30 pm - 6:00 pm 

    ABAM - The Next Generation Award Reception

    Lake Lucerne, Lobby Level


    Pain and Addiction CoursePlanning Committee Meeting

    Orlando Ballroom IV-V, Lower Level


    5:30 pm – 6:30 pm


    Public Policy Committee Meeting

    Lake Monroe, Lobby Level


    6:00 pm – 7:00 pm

    ASAM Review Course Program Planning Committee Meeting

    Celebration, Lobby Level


    6:00 pm – 8:00 pm

    Welcome Reception in the Exhibit Hall — Exhibit Hall Open

    Orlando Ballroom I-II, Lower Level


    Join friends and colleagues for the grand opening gala of ASAM’s 45th Annual Medical-Scientific Conference Exhibit Hall. Tour nearly one hundred exhibits and ASAM’s largest collection of poster presentations assembled to date. The Exhibit Hall is the vibrant hub of networking activity throughout the conference. Visit the ASAM booth and discover a world of resources, publications and ASAM merchandise.


    6:30 pm – 7:30 pm

    Chapters Council/Policy Roundtable Meeting

    Lake Concord, Lobby Level


    7:00 pm – 8:00 pm

    Ruth Fox Endowment Scholarship Meeting

    Lake Hart B, Lobby Level


    7:30 pm – 8:30 pm

    Component Sessions 1

    Influencing Health Policy: ASAM Advocacy in 2014

    Kelly Clark, MD, MBA, DFASAM, DFAPA; Alexis Geier-Horan, MPP; Scott Teitelbaum, MD, FAAP, DFASAM; Carol McDaid, Principal

    Lake Sheen A, Lobby Level

    ASAM plays an active and vital role in helping to shape state and federal policies that promote addiction prevention, treatment and recovery. Each year, the Legislative Advocacy Committee (LAC) identifies and prioritizes legislative and regulatory issues that impact the public’s ability to access treatment and our members’ ability to practice addiction medicine. The LAC then coordinates this agenda with the Public Policy Committee, to ensure that our policy compendium remains relevant and useful, and with the Chapters Council, to ensure our priorities also reflect what is happening at the state level. This session presents and expands on ASAM’s 2014 advocacy priorities and initiatives and the interrelationship between the society’s advocacy, public policy, and chapter relations programs. ASAM members are invited to provide input regarding current policy issues affecting their patients and practices. Member feedback may inform the implementation of the 2014 government relations (GR) initiatives as well as the development of ASAM public policies and GR priorities for 2015. Participants are also encouraged and equipped to engage in ASAM’s advocacy activities at the federal and state level.


    7:30 pm – 8:30 pm

    Component Sessions 2

    Use of Prescribed and Non-Prescribed Substance in Pregnancy

    Carl Christensen, MD, PhD, DFASAM; Loretta Finnegan, MD, LLD, ScD; Karol Kaltenbach, PhD; Tricia Wright, MD, MS; Catherine Friedman, MD

    Lake Sheen B, Lobby Level

    The existence and treatment of addiction when it occurs during pregnancy are arguably some of the most socially and legally controversial topics in medicine. This issue is further complicated when substances identified with addiction are prescribed to treat other disorders and/or as replacement therapy in pregnancy. A conflict between the needs of the pregnant woman/mother and the fetus/infant is often assumed. The media devotes significant, and often inaccurate, attention to such issues and state legislation, individual case rulings, and federal regulations often involve these issues. As would be expected, a good deal of the work of the Women and Substance Use Disorders Action Group focuses on responding to such legal and media initiatives. This Action Group works tirelessly to educate media and legislators and to educate clinicians and others about these topics. This component session will focus on such two areas: 1) Recent regulatory attempts to warn and to educate patients and providers about neonatal abstinence syndrome using the black box warning system and 2) "Medical" marijuana and potential legal and medical implications both for the mother and the infant when used in pregnancy.


    7:30 pm – 8:30 pm

    Component Sessions 3

    Quality Improvement: Improving Patient Care with Standards, Performance Measures and Guidelines

    Margaret Jarvis, MD, DFASAM; Michael Miller, MD, DFASAM, FAPA; R. Corey Waller, MD, MS, FACEP; Sandrine Pirard, MD, PhD, MPH; H. Westley Clark, MD, JD, MPH, CAS, DFASAM

    Lake Highland A, Lobby Level

    Promoted by the Affordable Care Act (ACA), health care is witnessing a shift towards increased accountability for physicians and other clinicians and a shift in payment involving Medicare and other payers paying hospitals and physicians for clinical performance and patient outcomes rather than the volume of services. Therefore, it is imperative that the field of addiction medicine develop its own standards of care and performance measures to improve patient care and outcomes. ASAM has met this challenge by establishing the Practice Improvement and Performance Measurement Action Group (PIPMAG), which has developed a document on Standards of Care for the Addiction Specialist Physician that addresses components of the clinical process such as assessment and diagnosis, withdrawal management, treatment planning, treatment management, care transitions and care coordination, and continuing care management. In addition, the document emphasizes the role of leadership and professionalism in the addiction medicine field. This session will provide attendees an overview of the standards, current performance measures and guidelines and examples of how they will help improve patient outcomes. There will be a discussion about implementation and how this effort will affect all levels of health care, including patients and physicians, the health care system, medical quality initiatives, specialty certification, payment reform, and public policy.


    7:30 pm – 8:30 pm

    Component Sessions 4

    FACULTY PRESENTERS – Are you an Expert at Content but Looking for Creative Ways to Engage, Inform and Inspire Learners?

     Abigail Herron, DO; Mario San Bartolomé, MD, MBA

    Orange Ballroom AB, Lobby Level

    Research has demonstrated that engaging learners increases their attention and focus, promotes knowledge retention, motivates them to practice higher-level critical thinking skills, and promotes meaningful learning experience outcomes. Active learning requires participants to engage in the session as opposed to sitting and listening. One popular style is case-based learning which utilizes clinical cases to stimulate inquiry, critical thinking, and knowledge application/integration. Other dynamic styles of immersing the learner in the content will also be explored. Come to this session where ideas on how to captivate, inform and inspire learners will be shared in an interactive environment. This session was created as a goal of the ASAM Medical Education Council to help presenters/faculty expand their teaching style and improve the quality of the learner experience.


    7:30 pm – 8:30 pm

    Component Sessions 5

    Using Motivational Incentives in Adolescent Treatment

    Marc Fishman, MD, DFASAM; David Lott, MD, DFASAM; Hoa Vo, PhD

    Lake Highland B, Lobby Level

    Motivational Incentives, also referred to as Contingency Management (CM), is a powerful treatment approach for substance use disorders (SUD) with consistent empirical support and large effects. Motivational Incentives improve patients' motivation for change by offering tangible prizes following therapeutically appropriate behaviors. Although this behavior change model has been extensively demonstrated in adults to reduce ongoing drug use and increase retention in SUD treatment, it has not been well examined in adolescents. In this session presenters will present on the background and principles of CM, the emerging research on CM in adolescents, practical implementation in community treatment, and discuss implications for dissemination in real world settings. The session will feature an interactive format and opportunities for audience participation, with time for discussion of practical logistics, differences in implementation between adolescent and adults, possibilities for family-based CM implemented by parents, and possibilities for using CM principals more broadly in treatment. Emphasis will be placed on the business case for the use of incentives that might make their use viable and productive in real world community settings by increasing attendance and revenue. This component session will provide an important learning opportunity and help participants take advantage of a powerful but underutilized treatment approach that may have particular applicability to adolescents.


    7:30 pm – 8:30 pm

    Component Sessions 6

    American Board of Addiction Medicines Diplomate Web Portal: Completing ABAM MOC Requirements

    Lia Bennett, MPH

    Orange Ballroom C, Lower Level

    Interactive presentations will focus on the establishment and launch of a new state-of-the-art ABAM Candidate and Diplomate Web Portal. This Web-Portal delivers a more streamlined and value- added experience for Diplomates and Candidates. ABAM will demonstrate features of the Diplomate Web Portal, such as an evidence-informed credit system that increases physicians’ choices for learning. Presenters will also show how the Diplomate Web Portal serves not only as a tool to assist Diplomates in meeting their MOC requirements, but also as a mechanism that will allow for continuous professional development in the field of addition medicine, ultimately improving the quality of care Diplomates provide to patients and their families. Participants in this session will also learn about the current requirements for Parts I,II, and III of MOC and the future plans for Part IV of MOC.


    8:45 pm – 9:45 pm

    Women & Substance Use Disorders Action Group Meeting

    Celebration, Lobby Level

    8:45 pm – 9:45 pm

    Component Sessions 7

    Adapting Twelve-Step Approaches to Specific Clinical Populations

    Marc Galanter, MD, DFASAM; Eric Collins, MD; Richard Ries, MD; Marvin Seppala, MD, PC

    Lake Sheen A, Lobby Level

    Twelve-Step programs such as Alcoholics Anonymous and Narcotics Anonymous have been found to be useful adjuncts to professional treatment, and the modality of Twelve-Step facilitation was successfully developed and applied to singly diagnosed patients. Clinicians, however, are currently dealing with substance dependent patients with diverse additional primary or secondary diagnoses. This puts a new importance on clinicians gaining facility in tailoring their clinical skills to frame approaches which make use of AA or NA for the complex clinical problems presented by such patients. This session is framed to enhance the capacity of attendees to adapt the Twelve-Step technique to suit a variety of patients. Presenters will employ four specific clinical examples to demonstrate the adaptability of the Twelve-Step program: persons diagnosed with social anxiety, inpatient rehabilitation settings, Twelve-Step involvement for suboxone treated patients, and addicted adolescents.


    8:45 pm – 9:45 pm

    Component Sessions 8

    The Providers’ Clinical Support System for Medication Assisted Treatment (PCSS-MAT): Increasing Access to Quality MAT

    Daniel P. Alford, MD, MPH, FACP, DFASAM; Edwin A. Salsitz, MD, DFASAM

    Lake Sheen B, Lobby Level

    PCSS-MAT is a SAMHSA funded national training and mentoring project developed in response to increases in prescription opioid misuse and heroin use and the underutilization of effective pharmacotherapies (methadone, buprenorphine, naltrexone) for opioid use disorders. The overarching goal of PCSS-MAT is to increase access to high quality MAT to manage patients with opioid use disorders in a variety of settings, including primary care, psychiatric care, and pain management settings. This component session will update participants on the newly revised PCSS-MAT program, including ASAM's role, and provide a forum for open discussion on how to improve the effectiveness of this training and mentoring program.


    8:45 pm – 9:45 pm

    Component Sessions 9

    The New ASAM Criteria and ASAM Criteria Software

    Susan Blank, MD; Paul Earley, MD, DFASAM; Marc Fishman, MD, DFASAM; David Gastfriend, MD; David Mee-Lee, MD; Michael Miller, MD, DFASAM; Gerald Shulman, MA, MAC, FACATA

    Lake Highland A, Lobby Level

    The ASAM Criteria is the most widely used and comprehensive set of guidelines for assessment, service planning, placement, continued stay and transfer/discharge of patients with addictive disorders. A new edition was released in October 2013 and new companion software tools will be released in 2014. Attendees will learn to incorporate the diagnostic tools, classifications and standards for patient care detailed in The New ASAM Criteria and software to develop specific treatment plans that will enhance patient outcomes. This session will explain and emphasize the new features, innovations, and changes present in this latest edition that were not in the last edition, the ASAM PPC-2R. Time will be allotted for a robust discussion of some of the newest features including: tobacco use disorder, gambling disorders and application to special populations such as, older adults, criminal justice settings, parents with children, and safety sensitive occupations.


    8:45 pm – 9:45 pm

    Component Sessions 10

    ABAM Maintenance of Certification (MOC) Part IV: Addiction Medicine Practice Performance Assessment

    Lia Bennett, MPH; Richard Blondell, MD; Judith Martin, MD, DFASAM; Michael Miller, MD, DFASAM; Cara Poland, MD; Jeffery Wilkins, MD, DFASAM, DFAPA

    Lake Highland B, Lobby Level

    Quality and safety in medical care have become a national priority. By requiring board certified physicians to participate in post-certification examination practice quality improvement initiatives, including participation in Practice Improvement Modules (PIMs), addiction medicine physicians are able to demonstrate their use of evidence-based practices and be compared to their peers and national benchmarks. More importantly, demonstrated participation in quality improvement initiatives assures the public they are receiving high quality health care from physicians who are knowledgeable in the latest advancements, research and technologies in their specialty. ABAM anticipates the implementation of Part IV: Practice Performance Assessment into the continuous professional development cycle of the MOC Program as early as 2015. This presentation will provide the groundwork for understanding the principles surrounding practice performance assessment and its role in the field of addiction medicine. The incorporation into MOC Part IV of ASAM’s Standards of Care for the Addiction Specialist Physician, developed through a multi-committee process funded by NIDA, SAMSHA and NIAAA will also be discussed.


    8:45 pm – 9:45 pm

    Component Sessions 11

    Integration of Addiction Medicine into Primary Care: New Approaches and Opportunities

    Ilene Robeck, MD; Peter Selby, MBBS, CCFP, FCFP, DFASAM; Norman Wetterau, MD, DFASAM

    Orange Ballroom AB, Lower Level

    Integration is the key buzzword in this component session. People are beginning to recognize that substance use disorders are a major health problem but aren’t seeing ways that they can be treated in the primary care setting. Can these substance use disorders really be addressed through primary care? Presenters will discuss their personal experiences integrating addiction treatment into primary care. Topics of discussion will include: addressing implementation challenges in Canada, including a discussion of design and systems thinking; e-consulting, clinical video-tele-consulting, and the VAscan program for primary care providers; and ASAM’s involvement in the Patient Centered Primary Care Collaborative’s effort to have substance use disorders addressed in primary care. The session will leave considerable time for those present to share their activities and ideas.


    8:45 pm – 9:45 pm

    Component Sessions 12

    ASAM Drug Testing White Paper

    Robert DuPont, MD, DFASAM

    Orange Ballroom C, Lower Level

    Recognizing that drug testing is the under-used technology of addiction medicine, ASAM published a Drug Testing White Paper on December 12, 2013 to catalyze wider and smarter use of drug testing with a primary focus on drug testing in health care. Though not a clinical guideline, the White Paper does explore the wide range of applications for drug testing and its utility in a variety of medical and non-medical settings. Furthermore, ASAM’s White Paper promotes the use of drug testing as a primary prevention, diagnostic and monitoring tool in the management of addiction or drug misuse in medical practice. This historic publication guides ASAM’s mission to improve the nation’s public health by promoting prevention, treatment and lasting recovery. A key focus of the session will be on a description of the rapidly evolving drug testing technology and how it relates to the even more rapidly evolving patterns of drug use including the spread of prescription drug abuse and the emergence of designer drugs, drugs designed to evade drug laws and drug tests.


    10:00 pm – 11:00 pm

    Mutual Help Meeting

    Lake Lucerne, Lobby Level


  • Friday, April 11, 2014

    7:00 am – 8:00 am

    Mutual Help Meeting

    Lake Lucerne, Lobby Level


    7:00 am – 6:00 pm

    Registration Open

    Orlando Ballroom, Lower Level


    7:00 am – 8:30 am

    ASAM Members Annual Business Meeting and Breakfast

    Orlando Ballroom V-VI, Lower Level

    (ASAM members only – breakfast service from 7:00 am – 8:00 am)

    Begin the first full conference day with breakfast; learn about the state of the organization; take part in “table conversations” with members of the ASAM Board; and hear an update from the American Board of Addiction Medicine. Meet the recipients of the Ruth Fox Scholarship and celebrate the recognition of many of our dedicated volunteers.


    8:30 am – 10:00 am

    Opening Scientific Plenary: R. Brinkley Smithers Distinguished Scientist Award and Lecture

    Orlando Ballroom III, Lower Level

    Stuart Gitlow, MD, MPH, MBA, FAPA, President of ASAM will set the stage for this year’s theme “Innovation and Integration Strategies in Addiction Medicine” with an overview of the state of the profession and the most pressing issues that impact care of patients with addiction disorders.

    ASAM will honor Shelly Greenfield, MD, MPH, as the recipient R. Brinkley Smithers Distinguished Scientist Award. This award recognizes and honors an individual who has made highly meritorious contributions in advancing the scientific understanding of alcoholism, its prevention and treatment. Dr. Greenfield will deliver her lecture, “Gender Differences in Addiction: Implications for Women's Addiction Treatment.”

    The prevalence of substance use disorders has increased in women since the mid-20th century with women initiating their use at earlier ages than in prior decades and currently at the same rates as men. However, women experience an accelerated course of addiction to many substances. The phenomenon in which women progress more rapidly from first use to the onset of dependence and first treatment compared to men has been labeled “telescoping." This telescoping course of addiction has implications for screening, early detection, and treatment. Gender differences in the current prevalence of and risk factors for substance use disorders and treatment services delivery will be reviewed, as will evidence for the use of women-focused treatment for women with addiction.

    Dr. Greenfield is a Professor of Psychiatry at Harvard Medical School and serves as Principal Investigator and Co-Investigator on federally funded research focusing on treatment for substance use disorders, gender differences in substance disorders, and health services for substance disorders. She has several leadership roles at McLean Hospital in Belmont, MA, serving as the hospital's Chief Academic Officer as well as the Director of Clinical and Health Services Research and Education in the Alcohol and Drug Abuse Treatment Program, Division on Alcohol and Drug Abuse. Dr. Greenfield is the former Associate Clinical Director of the Alcohol and Drug Abuse Treatment Program and director of the outpatient substance abuse treatment program and consultation services. From 2005-2010, she was also Director of the Harvard Medical School/Partners Addiction Psychiatry Fellowship and directed the substance abuse clinical rotations of the Adult Psychiatry Residency Program of Massachusetts General and McLean Hospitals.

    Dr. Greenfield served as the Founding Scientific Director of National Alcohol Screening Day. She is a former Chair of the American Psychiatric Association's Council on Addiction Psychiatry, and is a member of the Board of Directors of the American Academy of Addiction Psychiatry. She is Editor-in-Chief of the Harvard Review of Psychiatry and is a Distinguished Fellow of the American Psychiatric Association.

    Celebrate the achievements of this established researcher, teacher and clinician and benefit from her enlightening lecture!

    Federal Agency Perspectives:

    The session will conclude with perspectives from the three key federal agencies that most affect the field. Learn about the latest research, policy and treatment initiatives from agency leaders.


    George F. Koob, PhD, will share his reflections as the first Editor-in-Chief for the Journal of Addiction Medicine and his vision and goals as the new Director for the National Institute on Alcohol Abuse and Alcoholism (NIAAA).


    Wilson Compton, MD, MPE, recently appointed Deputy Director of the National Institute on Drug Abuse (NIDA), will outline NIDA's research and treatment innovation goals.


    H. Westley Clark, MD, MPH, CAS, DFASAM, Director, CSAT will share his thoughts on integration and innovation as they relate to SAMSHA’s vision and goals.

    Don't miss this illuminating and informative session that will set the tone for Med-Sci 2014!


    10:00 am – 6:00 pm

    Exhibit Hall Open

    Orlando Ballroom I-II, Lower Level


    10:00 am – 10:30 am

    Refreshment Break in the Exhibit Hall

    Orlando Ballroom I-II, Lower Level


    10:30 am – 12:30 pm

    Symposium 1

    There’s an App for That! Using Technology in Addiction Prevention and Treatment

    Christina Delos Reyes, MD; David Gustafson, PhD; Joshua Lee, MD, MSc; Lisa Marsch, PhD; Jennifer McNeely, MD, MS; Gail Rose, PhD

    Orange Ballroom A, Lower Level

    Advances in technology are progressing at a dizzying pace. In the addiction field, many researchers and clinicians on the front lines have begun to explore how the latest technology can be used in new and creative ways. This symposium will share the latest evidence about the use of technology in addictive disorders. There will be a particular emphasis on the use of technology in addiction prevention, screening, treatment, and relapse prevention. Additionally, participants will be introduced to some user-friendly and evidence-based applications (apps) that are available or in development for smart phones, tablets, and other electronic devices. Panelists and symposium organizers will also discuss the implications of emerging technology for the future practice of addiction medicine.



    Course 1

    Hot Topics in FDA Regulations and Pharmacotherapy Research that Impact Patient Care

    Michelle R. Lofwall, MD; Sharon Walsh, PhD; Shanna Babalonis, PhD

    Orange Ballroom B, Lower Level

    While reviewing hot topics in FDA regulations such as abuse deterrence and FDA requirements for abuse liability testing and post-marketing surveillance for new pharmacotherapies coming to market, Dr. Walsh will explain these requirements and offer first-hand accounts of her experience as a current FDA advisory board member. Understanding these regulations also requires understanding of the concepts of abuse potential, abuse liability, reinforcement, and potency. These concepts will be defined and illustrated through recent clinical research evaluating commonly abused drugs and pharmacotherapies for addiction treatment. Specifically, Dr. Babalonis will share her recent NIH-funded research evaluating the abuse potential of oxymorphone and tramadol in non-dependent recreational opioid users. Dr. Lofwall will discuss the abuse liability and potential therapeutic effects of tramadol among persons undergoing opioid withdrawal, and how current regulations impact off-label use of tramadol for opioid addiction treatment. Dr. Walsh will discuss the impact of naloxone in buprenorphine formulations under a variety of conditions. Overall, addiction medicine physicians will begin to understand the benefits, limitations and consequences of FDA regulatory control of drugs of abuse, learn how clinical research can inform patient care, and learn how patient cases can then inform future research and regulatory policy.



    Symposium 2A

    Update on Women's Issues – Part I

    Joan Ellen Zweben, PhD; Catherine Friedman, MD; Shelly Greenfield, MD, MPH; Lisa Najavits, PhD
    Sponsored by: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    Orange Ballroom D, Lower Level

    In the first part of this dynamic two-part symposium, Dr. Greenfield will speak on "Gender differences in addiction and its treatment" and provide an overview of women and substance abuse treatment. She will discuss recent epidemiologic trends including the narrowing of the gender gap in prevalence of these disorders as well as gender differences in risks for substance use disorders. Dr. Greenfield will present an overview of evidence based screening and treatments for women with substance use disorders. Single gender group therapy for women and new findings from the Women’s Recovery Group Study will also be discussed. Dr. Najavits will summarize the key findings from her comprehensive review of the treatment outcome literature on SUD and PTSD. Results showed positive outcomes on multiple domains, but most models had more impact on PTSD than SUD. Dr. Friedman will focus on issues of substance use and pregnancy, and the resulting social, medical and legal consequences of this use on the mother, her infant and the family. She will describe the recent activities of the Women and SUD Action Group, such as the very recent FDA black box placed on long-acting opioids and NAS, efforts to educate clinicians and legislators on these topics, and bring more of an evidence base and a basis in clinical reality to these concerns.



    Course 2

    Synthetic Cannabinoids: Spice for Youngsters but Nightmare for Clinicians, Researchers, and Legislators

    Sandrine Pirard, MD, PhD, MPH; Erik Gunderson, MD, DFASAM

    Orange Ballroom G, Lower Level

    Synthetic cannabinoids (SC), sold under many names such as Spice, K2, and fake weed, are designed to mimic the effects of cannabis by targeting the cannabinoid receptors in the brain. These products often contain a mixture of dried plant material and synthetic cannabinoid compounds which are responsible for the psychoactive effects. Documented use of SC has surfaced over the last few years, in particular among young people. Reported effects associated with SCs, some of which are cannabis-like, range from mild to severe and life-threatening. These effects, however, are largely based on anecdotal evidence, and no carefully controlled human exposure study has been published so far. Hundreds of compounds with various chemical structures have been marketed making it extremely hard for researchers to study and for legislators to regulate. Presenters will discuss epidemiological data on the use of synthetic cannabinoids, describe the range of clinical effects that have been linked to the use of these drugs, and also review the complexity behind the identification and regulation of SC. Finally, the current state of research on SC and the means to address the barriers to conducting clinical research to better understand these compounds will be explored.



    Workshop 1

    How to Work (and Win) with the Media

    Patricia Clark, MS, BS

    Orlando Ballroom IV, Lower Level

    From the legalization of marijuana to the rise in prescription drug overdose deaths, never has the media's demand for addiction medicine experts been higher. Ill-informed or biased reporting on celebrity overdose deaths, marijuana’s “medicinal” value and America’s ongoing “war on drugs” is currently shaping the way Americans, including its policymakers, perceive addiction. Often absent from new stories are scientific and medical opinions about the realities of addiction and the benefits of evidence-based treatment. This interactive media training session offers practical tips and on-camera techniques for telling ASAM’s story and for promoting your specialty. You will learn how to develop your message; how to control a media interview or public testimony; how to dress and act when you step before the cameras; and, most importantly, how to deliver that message successfully.



    Specialized Two-Part Course

    Clinical Drug Testing in Medical Care – Part I: What You Need to Know –

    Michael Sprintz, DO; M.P. George, MS; Louis E. Baxter, Sr., MD, DFASAM

    Orange Ballroom C, Lower Level

    More than 20 million forensic drug test specimens are processed by certified laboratories every year, and the results of these laboratory tests are reviewed and interpreted by more than 6,000 physicians. Drug testing is not only a tool in the doctors bag for addiction medicine specialists but it should be used by every physician involved in direct patient care. Proper interpretation of drug test results can help knowledgeable physicians diagnose, treat, and monitor the recovery of their patients. This course provides the basis for the understanding and interpretation of the tool of drug testing. Whether a physician is certified in addiction medicine or in another medical specialty there is no more important and potentially life-changing role a physician can play than the application and interpretation of drug testing. Presented in two 2-hour segments, course participants will learn the value of drug testing in general practice and understand how to apply drug testing as both a deterrent to patients as well as a useful tool in monitoring on-going patient care. The most up-to-date information regarding new designer drugs as well as the subtleties of interpreting tests for prescription drug misuse will be explored. Through interactive, case-based presentations participants will discover how interpret test results and how best to discussion those results with patients. Finally participants will learn the clinical implications of test results and the pros and cons of each testing medium.


    10:30 am – 10:50 am
    Introduction and Overview
    Michael Sprintz, DO
    Prescription drug abuse—Your License and Your Patients’ Lives; The importance of Clinical Drug Testing in Current Medical Practice; Course Overview

    10:50 am -11:35 am
    The Science of Drug Testing
    M.P. George, MS

    POCT vs. Immunoassay vs. Quant (LC/MS); Matrices--focus on urine, oral fluid and hair; Limits false positives/false negatives; Which Drugs are Missed on Screens; How Patients Beat Drug Tests

    11:40 am – 12:20 pm
    Clinical Drug Testing Basics
    Michael Sprintz, DO
    Which Patients to Test; When to Test; Choosing Which Drugs to Test For; Use of Drug Testing in Conjunction with Other Tools

    12:20 pm – 12:30 pm
    Morning Session Wrap-up; Q&A
    Michael Sprintz, DO; Louis E. Baxter, Sr., MD, DFASAM; & Faculty


    Note: Attendance is encouraged at both Part I and Part II of this two-part Course in order to benefit from both the theoretical and clinical practice aspects of the material presented.


    12:30 pm – 1:30 pm

    ASAM Sponsored Complimentary Grab n’ Go Luncheon in the Exhibit Hall

    Orlando Ballroom I-II, Lower Level

    12:45 pm – 1:45 pm

    Like-Minded Docs Meeting

    Orlando Ballroom IV, Lower Level


    12:30 pm – 2:30 pm


    2014 Poster Sessions in the Exhibit Hall

    Orlando Ballroom I-II, Lower Level


    Poster 1 – Quality of Life and Smoking

    Matthew Goldenberg, DO; Itai Danovitch, MD; Waguih William IsHak, MD, FAPA

    Poster 2 – Cigarette Smoking Knowledge, Attitudes, and Practices in Perinatal Substance Abuse Treatment Staff

    Margaret Chisolm, MD

    Poster 3 – Food Insecurity, Depression, and Social Support in HIV-infected Hispanic Substance Abusers

    Leonid Kapulsky, BS

    Poster 4 – Buprenorphine/Naloxone Maintenance Treatment for Loperamide Use Disorder

    Vamsi Garlapati, MD; R. Jeffrey Goldsmith, MD, DFASAM; Sajoy Varghese, MD

    Poster 5 – Two Cases of Adolescent Males with Severe Psychosis Triggered by Spice

    Mariam Rahmani, MD

    Poster 6 – Nurse Addiction - An Unexpected Journey: A Phenomenological Study of Nurses in Recovery

    Karen Lee Burton, PhD, RN, CNE

    Poster 7 – A Psychological Pain Based Treatment Allocation System in Outpatient Substance Abuse Treatment

    Steven Mee, MD

    Poster 8 – The Genetics of Binge Drinking: A Review of the Literature

    Matthew Sloan, MD; Joshua Ejdelman, MSc(c); Nancy Low, MD, MSc

    Poster 9 – Assertive Community Treatment with Buprenorphine for Opioid Dependence and Severe Mental Illness

    Troy Pulas, MD

    Poster 10 – Low-dose Naloxone: An Abuse Deterrent to Buprenorphine Doses Less than 1 mg

    Lynn Webster, MD

    Poster 11 – Buprenorphine/naloxone Buccal Film: a Novel Approach in the Treatment of Opioid Dependence

    Kent Hoffman, DO

    Poster 12 – Buprenorphine/naloxone Buccal Film: Relative Buprenorphine Bioavailability Approximately Twice that of Suboxone

    Niraj Vasisht, PhD

    Poster 13 – Misuse and Intoxication Due to Topical Ketamine

    Marc Myer, MD; Pamela Shultz, MD

    Poster 14 – Comparison of Long-Acting Benzodiazepines and Phenobarbital for Inpatient Detoxification from Benzodiazepines

    Muhammad Ghazi, MD; Jennifer Harb, MD Candidate; Sanjay Jain, BS; Mohammed Reza Azadfard, MD

    Poster 15 – Improvement in Functional Outcomes after Residential Treatment Persists for 12 Months Post-discharge.

    Michael M. Miller, MD, DFASAM, FAPA

    Poster 16 – Drug Use in Pregnancy

    Charles Schauberger, MD, MS

    Poster 17 – Buprenorphine/Naloxone Pediatric Ingestion: Exposure Rates Differ Between Film and Tablet Formulations

    Eric Lavonas, MD

    Poster 18 – State Variation in Availability of Medications for Substance Use Disorder (SUD) Treatment

    Amanda Abraham, PhD; Traci Rieckmann, PhD

    Poster 19 – State Medical Board Policies on Opioid Maintenance Therapy for Recovering Physicians

    Cynthia Brown, MD; Christopher Adelman, MD; Joseph Lydon, MD; Mary Ellen Lyons, Medical Student;

    Poster 20 – Working Memory and Emotion Regulation in Opioid Dependent Youths

     Gabriella Barnett, BS; Marc Fishman, MD, DFASAM; Hoa Vo, PhD

    Poster 21 – Unobserved Buprenorphine Induction in a Primary Care Clinic: 7 Year Follow

    Joshua D. Lee, MD, MSc; Elenore Patterson, MD, MPH

    Poster 22 – Budgetary Impact of Buprenorphine/Naloxone Tablet Formulations for Private Health Care Plans

    Samuel Aballea, MSc; Emilie Clay, MSc; Amine Khemiri; Jane Ruby, PhD; Vladimir Zah, PhD

    Poster 23 – Homelessness and HIV: Predictors of Health Care Utilization for Substance Users

    Kinna Thakarar, DO, MPH

    Poster 24 – Butrans Patch Abuse Using RADARS Poison Center Program Data

    Timothy Wiegand, MD, FACMT

    Poster 25 – Krokodil: Is it here? From Russia with scare!

    Vishesh Agarwal, MD; Subani Maheshwari, MD

    Poster 26 – Characteristics and Treatment of Diabetic Patients Receiving Prescription Opioids for Pain

    Richard Blondell, MD; Rachel Stewart, BA

    Poster 27 – Substance Misuse in the Elderly: Retrospective Chart Review in Senior Recovery Track

    Gibson George, MBBS; Robert Kohn, MD; Padmapriya Musunuri, MBBS, MRC; Carolina Retamero, MD

    Poster 28 – Factors Affecting Treatment Outcomes in Elderly Illicit drug users: A Case Series

    Gibson George, MBBS; Padmapriya Musunuri, MBBS, MRC; Carolina Retamero, MD; Marc Zisselman, MD

    Poster 29 – Marijuana's Role in Relapse with Illicit Opiates

    Barbara Herbert, MD; Paul Pyzowski, BSEE, MBA

    Poster 30 – Gambling Disorder: The real stakes! Possible Opening of New Casino in Philadelphia

    Vishesh Agarwal, MD; Subani Maheshwari, MD;

    Poster 31 – Methamphetamines and Birth Outcomes

    Tricia Wright, MD, MS

    Poster 32 – The New York ISTOP PMP and Effect on an Addiction Pharmacotherapy Program

    Timothy Wiegand, MD, FACMT

    Poster 33 – Identifying Opana ER Injection as Etiology for TTP-like Illness (Microangiopathic Hemolytic Anemia)

    Sehar Khokher, MD; Valerie Vestal, MSN, RN

    Poster 34 – A New Non-Opioid Protocol for Opioid Detoxification and/or Transition to Antagonist Treatment

    Gregory Rudolf, MD; James Walsh, MD; Abigail Plawman, MD; Vania Rudolf, MD

    1:00 pm – 2:00 pm

    Pain and Addiction Editors Meeting

    Lake George A, Lobby Level

    1:00 pm – 2:30 pm

    CME Committee Meeting

    Lake Florence B, Lobby Level

    1:30 pm – 2:30 pm

    Principles of Addiction Medicine Editorial Meeting

    Lake Florence A, Lobby Level

    2:30 pm – 4:30 pm

    Symposium 2B

    Update on Women's Issues – Part II: From FASD to the Golden Years

    Deidra Roach, MD, moderator; Stacy Sterling, MPH, MSW; Mary McCaul, PhD; Sandra Jacobson, PhD

    Sponsored by: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    Orange Ballroom D, Lower Level

    The afternoon session focus on consequences and subgroups of women’s drinking. The most serious consequences of drinking during pregnancy are fetal alcohol spectrum disorders (FASD), including fetal alcohol syndrome (FAS). Children with FASD have been found to have growth retardation, central nervous system problems, facial abnormalities, behavioral and academic problems, and psychosocial problems. These deficits are lifelong and not easily treatable. Dr. Sandra Jacobson will discuss the latest findings from research on FASD, with special emphasis on the latest developments in screening and diagnosis, referral to treatment, and promising approaches to treatment. Adolescent girls are particularly vulnerable to the harmful effects of excessive drinking. In addition to describing findings taken from a large, integrated health system, Stacy Sterling will discuss results from a comparative effectiveness trial of adolescent screening, brief intervention and referral to treatment (SBIRT), focusing on gender differences in presentation of problems in pediatric primary care, and SBIRT practices among pediatricians. In particular, women with co-occurring HIV, alcohol misuse, anxiety, and depression are populations of growing public health importance. Dr. Mary E. McCaul will provide an overview of the current research on HIV-infected women with co-occurring alcohol misuse and other mental health disorders, emphasizing co-occurring anxiety and depression.



    Symposium 3

    Neuropsychiatric Complications of HCV Among Drug Users

    Jeffrey Samet, MD, MA, MPH; Igor Grant, MD; Jag Khalsa, PhD, MS; Glenn Treisman, MD, PhD; Judith Tsui, MD, MPH

    Orange Ballroom A, Lower Level

    Hepatitis C virus (HCV) infection is one of the most serious comorbidities associated with drug use. Many people who regularly abuse drugs are also diagnosed with mental disorders and vice versa. The high prevalence of this comorbidity has been documented in multiple national population surveys since the 1980s. Among the extra-hepatic manifestations of HCV, neuropsychiatric complications are common and can be vexing. In particular, HCV-infected individuals have cognitive, depressive and pain symptoms, complicating optimal addiction and other medical treatment. The session will address three domains of neuropsychiatric involvement among HCV-infected patients. Dr. Glenn Treisman will review mood disorders, in particular depression. Dr. Judith Tsui will discuss pain and quality of life challenges and Dr. Igor Grant will share data about cognitive function among HCV-infected drug users. The impact of the disease and the treatment (interferon/ribavirin) will be discussed for each domain.



    Paper Session – Group I


    Orange Ballroom G, Lower Level


    Session 1 – Outpatient Induction to Extended-Release Naltrexone (XR-NTX) in African American Opioid Dependent Patients

    Paolo Mannelli, MD

    Session 2 – Hispanic Ethnicity Is Associated With Poor Adherence to Opiate Addiction Treatment Programs

    Hari Krishna Raju Sagiraju, MD, MPH; Bertram W. Roberts, MD, Brittny Wolda

    Session 3 – Suicide and Harm Reduction in Aboriginal Communities, Hudson Bay, Northern Canada

    Arnold Hill, MD, MSc, DFASAM; Charleen Banayan, MD

    Session 4 – Substance Misuse in the Elderly: Retrospective Chart Review in Senior Recovery Track

    Padmapriya Musunuri, MBBS, MRC; Gibson George, MBBS; Carolina Retamero, MD; Marc Zisselman, MD; Robert Kohn, MD

    Session 5 – High School Student Designer Drug Use and School Climates Regarding Substance Use

    Shonali Saha, MD




    Workshop 2

    Achieving Systemic Change through Development of Addiction Medicine Fellowships

    Andrew Danzo, BA; Richard Blondell, MD; Scott Teitelbaum, MD, FAAP, DFASAM; David Withers, MD; Kevin Kunz, MD, MPH, DFASAM; Patrick G. O’Connor, MD,MPH

    Orlando Ballroom IV, Lower Level

    Expansion of accredited fellowship programs is crucial for achieving addiction medicine’s promise of integrating addiction prevention and care within mainstream healthcare. Perceived barriers to fellowship development include limited institutional support, insufficient funding for training stipends, and lack of prior experience in implementing and administering a graduate medical education program. This workshop will address these and related issues, as it takes participants through the process of launching an accredited fellowship in addiction medicine. The session is designed for physicians interested in starting an addiction medicine fellowship at their local hospital or medical school; physicians interested in teaching in a fellowship; and physicians, residents, or students interested in training in an addiction medicine fellowship. Nineteen addiction medicine fellowships have been accredited in the past three years and more are expected. These programs, with 45 fellows already graduated or in training, demonstrate that a robust infrastructure for graduate medical education in addiction medicine is feasible, with fellowships following various organizational models while adhering to common national standards. Audience members will learn how these programs are positioning themselves for future ACGME recognition and enhancing the role of addiction medicine in their host institutions.



    Collaborative Workshop

    Society of General Internal Medicine (SGIM)

    Incorporating Harm Reduction into Addiction Medicine Practice

    Sarah Wakeman, MD; Sharon Stancliff, MD; Alexander Y. Walley, MD; Sarah Bagley, MD

    Orange Ballroom B, Lower Level

    In an effort to improve patient care and physician preparedness, this session will feature an overview of principles and examples of harm reduction and the evidence supporting its efficacy. Using case-based examples, presenters will review specific interventions that could be integrated into an addiction medicine practice including, overdose prevention and naloxone rescue kits, crack cocaine kits, and low threshold treatment models. Attendees will learn how to educate their patients about safer syringe and needle access and safer injection techniques. Presenters will also discuss current campaigns to reduce stigma in healthcare settings and to empower commercial sex workers to protect themselves. To effectively teach these techniques and enhance confidence in implementing these into practice, session participants will split into small groups to practice skills. Each group will rehearse teaching overdose prevention, intranasal naloxone administration techniques and safer injection techniques. Groups will have robust discussions about barriers and facilitators to incorporating the harm reduction approach and interventions into their practices. The workshop facilitators will observe and offer constructive feedback to each group of participants. The workshop will conclude with a summary of key take home tips and a list of online resources for further reference.



    Specialized Two-Part Course

    Clinical Drug Testing in Medical Care – Part II: What You Need to Do

    Louis E. Baxter, Sr., MD, DFASAM; Susan Neshin, MD; Lawrence Brown, Jr., MD, MPH, DFASAM; Michael Sprintz, DO

    Orange Ballroom C, Lower Level

    During the second session of this two 2-hour workshop program, participants will understand how to apply drug testing as both a deterrent to patients as well as a useful tool in monitoring on-going patient care. Particular emphasis will be made on what the physician should do with test results, how to interact constructively with patients and how to incorporate testing into ongoing patient care. Through interactive, case-based presentations participants will discover how interpret test results and how best to discuss those results with patients. These workshop sessions will provide practical, hands-on competencies that will be immediately applicable in the clinical setting and will result in immediate impact on patient outcomes. Part I will provide an overview of drug testing and toxicology in the clinical setting, including the "nuts and bolts" or choosing the appropriate test and how to apply tests. Part II will emphasize the importance of proper test interpretation, communicating with patients in a meaningful and productive way and how to continue to apply testing in on-going patient care. Course materials will include valuable handouts, practical guidance for reimbursement, and access to useful resources available on the web.


    2:30 pm – 3:10 pm
    Case Study and Test Interpretation

    Louis E. Baxter, Sr., MD, DFASAM

    Case Study: New Patient with Low Back Pain from Work on Norco and Soma; Clinical Implications of Test Results; False Positive/Negative; To Prescribe or Not to Prescribe; State Laws Surrounding Prescribing to a Patient with a Suspected Substance Use Disorder


    3:10 pm – 3:40 pm

    Discussing Test Results with Patients

    Susan Neshin, MD

    Address POCT vs Confirmation; Family Members, Employers, and Other Healthcare Provider


    3:40 pm – 4:20 pm

    How to Apply Drug Testing in your Practice

    Lawrence Brown, Jr., MD, MPH

    Setting up Random Screening Protocol for Your Practice; Policies, Consents, and Compliance Paperwork; Billing; Relationship with Confirmatory Lab; When and If to Discharge a Patient Based on Drug Test; Referral to Addiction Medicine

    4:20 pm – 4:30 pm

    Course Wrap-up; Q&A

    Michael Sprintz, DO; Louis E. Baxter, Sr., MD, DFASAM & Faculty


    Note: Attendance is encouraged at both Part I and Part II of this two-part Course in order to benefit from both the theoretical and clinical practice aspects of the material presented.


    4:30 pm – 6:00 pm


    4:30 pm – 5:30 pm

    Journal of Addiction Medicine Editorial Meeting

    Lake Florence A, Lobby Level

    Pysician Health Committee

    Lake Lucerne, Lobby Level

    4:30 pm – 6:00 pm

    Networking Reception in the Exhibit Hall

    Orlando Ballroom I-II, Lower Level

    5:00 pm – 6:30 pm

    Medical Education Council Meeting

    Lake Monroe, Lobby Level

    6:00 pm

    Exhibit Hall Closes

    Orlando Ballroom I-II, Lower Level

    6:30 pm – 8:00 pm

    2015 ASAM Annual Conference Program Committee Meeting

    Lake Monroe, Lobby Level

    6:30 pm – 8:30 pm

    ASAM Donors/Ruth Fox Reception

    (by Invitation Only)

    Lake Highland, Lobby Level

    10:00 pm – 11:00 pm

    Mutual Help Meeting

    Lake Lucerne, Lobby Level


  • Saturday, April 12, 2014


    7:00 am – 8:00 am

    Mutual Help Meeting

    Lake Lucerne

    7:00 am – 5:00 pm

    Registration Open

    Orlando Ballroom Foyer, Lower Level

    7:00 am – 8:00 am

    Continental Breakfast in the Foyer

    Orlando Ballroom III Foyer, Lower Level

    7:00 am – 8:00 am

    ASAM Criteria Steering Committee Meeting

    Lake Florence A, Lobby Level

    7:00 am – 8:00 am

    Opioid Treatment Program Work Group

    Lake George A, Lobby Level

    8:00 am – 9:30 am

    ASAM Public Policy Plenary: Public Health Implications of Marijuana Legalization

    Orlando Ballroom III, Lower Level

    Twenty-one states and the District of Columbia have passed measures that legalize marijuana, for medicinal and/or recreational use and three more states are considering proposals to do the same in 2014. While ASAM opposes both the “medicalization” of marijuana and proposals that legalize marijuana for recreational use, health care professionals continue to debate the harms and benefits associated with this drug. Engage leading marijuana experts as they discuss the implications of marijuana legalization on public health and welfare.

    Organized by ASAM Public Policy Committee, Co-Chairs: Scott Teitelbaum, MD, DFASAM; Mark Kraus, MD, DFASAM. Welcome and introductions by ASAM President, Stuart Gitlow, MD, MPH, MBA, FAPA


    Robert DuPont, MD, DFASAM, FAPA--President, Institute for Behavior and Health; Former White House Drug Chief and Director, National Institute on Drug Abuse

    Kevin Sabet, PhD--Director, Drug Policy Institute at University of Florida; Co-founder, Project SAM

    Jeffrey Wilkins, MD, DFASAM, DFAPA—Vice Chair, Cedars Sinai Medical Center Department of Psychiatry and Behavioral Neuroscience; Immediate Past President, California Society of Addiction Medicine


    9:30 am – 12:00 pm

    Exhibit Hall Open

    Orlando Ballroom I-II, Lower Level

    9:30 am – 10:00 am

    Refreshment Break in the Exhibit Hall

    Orlando Ballroom I-II, Lower Level

    10:00 am – 12:00 pm

    Symposium 4

    President’s Symposium—Addiction Medicine Today *

    Stuart Gitlow, MD, MPH, MBA, FAPA, ASAM President & Moderator; Elinore F. McCance-Katz, MD, PhD, Chief Medical Officer, Substance Abuse and Mental Health Services Administration; Chad D. Kollas, MD, FACP, FCLM, FAAHPM, Medical Director of Palliative & Supportive Care, UF Health Cancer Center

    Orange Ballroom A, Lower Level

    Thought leaders will deliver TED-style talks that will focus on the issues and challenges in the addiction field. Topics may include opioid prescribing, overlap between addiction and pain, future pharmacologic directions, interface of government and addiction, applying guidelines to practice and other topics of interest and value to attendees. The goal of the session is to develop fresh insights on the critical strategic questions addiction professionals must confront as they lead the field into the next decade and beyond.

    This unique session includes rich exploratory discussions that will engage participants in understanding various perspectives, identifying new ideas and imagining new possibilities.

    ASAM President, Stuart Gitlow, MD, MPH, MBA, FAPA will moderate a dialog with the presenters as he explores their views on current and future implications on clinical practice, research and patient outcomes and the strategies to address these implications.

    * This highly interactive session will not be recorded and will not be available online through ASAM's e-LLC after the conference.



    Symposium 5

    International Perspectives on Addiction Medicine

    Marc Galanter, MD, DFASAM; Jag Khalsa, PhD, MS; Petros Levounis, MD, MA, DFASAM; Gavin Bart, MD, PhD, FACP, DFASAM; Nady el-Guebaly, MD, DFASAM; Jeffrey Samet, MD, MA, MPH

    Co-sponsored by: The International Society of Addiction Medicine (ISAM) and the National Institute on Drug Abuse (NIDA)

    Orange Ballroom B, Lower Level

    International clinical research on substance use disorders has seen remarkable growth in recent years. While some of this growth can be attributed to new modalities of treatment for the very same problems and disorders confronting American clinicians in the addiction field, other research studies are investigating problems different from our own, yet still ones that shed light on the issues confronted in the American treatment community. The membership of the International Society of Addiction Medicine (ISAM), established in 1998, includes a large, worldwide representation of addiction specialists who have regularly met to present and exchange their respective findings. ASAM, in conjunction with NIDA, will present findings from global clinical research and their clinically-applicable experiences that shed light on the problems we confront here in the United States. These presentations illustrate how we can broaden and extend our competency in addiction treatment and research by leveraging the unique experience drawn from the international arena. Participants will explore innovative aspects of clinical addiction medicine from an international perspective and discover the role of NIDA and ISAM in addiction care and research. As a result, they will become better able to provide and organize care for addicted patients.



    Symposium 6A

    Development Biologics to Treat Substance Use Disorders: An Update for Clinicians – Part I

    Ivan Montoya, MD, MPH; Bridget Ann Martell, MD, MA; Paul Pentel, MD; Chang-Guo Zhan, PhD

    Sponsored by: National Institute on Drug Abuse (NIDA)

    Orange Ballroom D, Lower Level

    Substance Use Disorders (SUDs) are complex medical conditions that require multiple treatment approaches. Currently, FDA-approved pharmacotherapies for these disorders have low efficacy (ie, nicotine and opioid use disorders) or are not available (ie, cocaine, methamphetamine and cannabis use disorders). The research of pharmacotherapies has traditionally focused on small molecules that target a receptor in the brain. A newer approach is the study of biologics such as vaccines, antibodies and enzymes to treat SUDs. The mechanism of action of biologics is by impeding the access of the drug of abuse to the brain and thus blocking its neurotoxic effects, including those on the brain reward pathways associated with addiction. Biologics have an important potential clinical advantage: they have a long duration of action and do not require daily dosing. Therefore, treatment adherence can improve significantly because patients do not have to remember to take a medication every day. Moreover, biologics can be combined with other psycho-pharmacotherapies because they do not interfere with their mechanism of action on the brain and thus lower the risks of untoward effects. The purpose of this two-part symposium is to review the current advances in the development of biologics to treat SUDs. It will include an introduction to the different treatment approaches with biologics, results of clinical safety and efficacy studies, and advances in optimizing strategies to develop biologics.

    Note: Attendance is encouraged at both Part I and Part II of this two-part Course in order to benefit from both the theoretical and clinical practice aspects of the material presented.



    Course 3

    Medically Assisted Treatment in Drug Courts

    Douglas Marlowe, JD, PhD

    Orlando Ballroom V, Lower Level

    Drug treatment courts are an increasingly important tool in reducing the census of those incarcerated for non-violent drug offenses; medication assisted treatment (MAT) is proven to be an effective treatment for opioid addiction. However, little is known about the availability of and barriers to MAT provision for opioid-addicted people under drug court jurisdiction. A recent national survey found that approximately 50% of drug courts use MAT, a rate several times greater than any other criminal justice program. However, attitudinal and practical barriers remain and the medical field has failed to address the major concerns about MAT commonly expressed by judges and other drug court professionals. This session will review the findings from the national MAT survey and describe the major barriers to implementation of MAT in drug courts and the criminal justice system.



    Workshop 3

    The Where, When, and Why of Alcohol Withdrawal: An Advanced Practice Workshop

    Timothy Wiegand, MD, FACMT; JoAn Laes, MD; Joseph Rasimas, MD; Beau Braden, DO, MPH, MS

    Orlando Ballroom IV, Lower Level

    Alcohol withdrawal has been long-recognized as a sequel of addiction that still produces troubling complications and demands medical resources with significant associated expense. A variety of pharmacological approaches have been proposed over the years and while some proponents routinely claim uniform success for their favorite regimens, the protocols seem not to take hold in other settings, where different routines hold sway. The presenters propose that there is wisdom in this observed practice variability, and suggest that differences in settings, resources, and goals of treatment should be viewed not as confounds to determining the single best approach to this syndrome, but as key treatment considerations that may inform a well-tailored plan specific to a given patient. To illustrate this, three cases will be examined, all involving patients at various points in their withdrawal and at varying levels of illness severity. There will be a focus on pharmacologic options with attention to both their pathophysiologic rationale and their practical utility in each scenario. Logistics of monitoring plans, the impact of comorbidity, and desired medical and behavioral endpoints will be considered. Use of non-traditional treatments for the management of alcohol withdrawal including, in particular, intravenous ethanol and the alpha-2 agonists, dexmedetomidine and clonidine, as well as other pharmacotherapy strategies such as front-end loading using phenobarbital, ketamine and use of propofol for ICU patients will be discussed.



    Paper Sessions - Group II

    Orange Ballroom C, Lower Level


    Session 1 – Impact of Emergency Department-Delivered SBI on Subsequent Involvement in Crime and Violence

    Aaron Johnson, PhD; Joanna Akin, MSPH; Paul Seale, MD

    Session 2 – A Primary Care Management Tool for Alcohol Use Disorders and At-Risk Drinking

    Sheryl Spithoff, BSc, MD, CCFP

    Session 3 – Using the Emergency Department as a Window into Community Behavioral Health

    Sheryl Davies, MA

    Session 4 – Clinical Integration of Innovative Genetic Risk/ Medical Monitoring in Reward Deficiency Syndrome

    Kenneth Blum, PhD; John Femino, MD, DFASAM, MRO; David Smith, MD, DFASAM, FAACT; A. Kenison Roy, III, MD, DFAPA, DFASAM

    Session 5 – Pilot Evaluation of Third Wave Modular Group Psychotherapy for Co-Morbid Clients

    Danielle Florida, MD, FRACGP



    12:00 pm - 2:00 pm


    ASAM Annual Awards Luncheon

    Price: $75/Per Person


    Orlando Ballroom III, Lower Level


    Celebrate the accomplishments of rising stars and distinguished leaders in the field of addiction medicine at the Annual ASAM Awards Luncheon. This plated luncheon is an opportunity to network with colleagues, draw inspiration from outstanding accomplishments and welcome new Fellows.


    John P. McGovern Award

    “To recognize and honor an individual who has made highly meritorious contributions to public policy, treatment, research, or prevention which has increased our understanding of the relationship of addiction and society.”

    Paul N. Samuels, JD


    Paul N. Samuels, recipient of the John P. McGovern Award, will address the gathering with the lecture on Addiction and Society. Mr. Samuels is Director/President of the Legal Action Center, a not-for-profit public interest law firm with offices in New York City and Washington, DC specializing in legal and policy issues involving alcohol and drug abuse and dependence, AIDS and criminal justice.


    For more than two decades Mr. Samuels has worked on a wide range of alcohol and drug policy issues at the federal, state, and local levels, including developing creative strategies to increase public and private financing for treatment and improve the quality of treatment, and working with government agencies, service providers, national organizations, and the recovery community to implement those strategies and educate the public and policymakers. He has testified before numerous Congressional and state legislative committees and lectured in more than 30 States on a range of policy issues related to alcohol and drug problems. Mr. Samuels has served on numerous national and state advisory groups, including the Expert Panel of CSAT’s National Treatment Plan, the Advisory Council of the National Institute on Alcohol Abuse and Alcoholism (NIAAA).


    Currently Mr. Samuels is the Co-chair of the Coalition for Whole Health and was appointed in June 2013 by Governor Andrew Cuomo to serve as the Chair of New York State’s new Behavioral Health Services Advisory Council. Mr. Samuels is the recipient of a number of awards, including the Robert Wood Johnson Foundation’s Innovator Combating Substance Abuse in 2002, AMERSA’s Betty Ford Award in 1998, and Awards from the National Association of State Alcohol and Drug Abuse Directors in 1998 and 1992. Mr. Samuels joined the staff of the Legal Action Center upon graduation from Columbia Law School in 1979. He became Executive Vice President in 1983 and Director/President in 1992. He is a graduate of Harvard College.


    Below are listed the recipients of this year's awards and recognitions. The ASAM Awards Luncheon is a celebration of the best and brightest in the field of addiction medicine.


    2014 Award Recipients


    R. Brinkley Smithers Distinguished Scientist Award

    “For individuals who have publicly shared the message of hope and the promise of help, and individuals whose work in the field of alcoholism has had a positive impact in the fight against America's most misunderstood disease.”

    Shelly Greenfield, MD, MPH


    ASAM Public Policy Award

    “For outstanding contribution in advancing addiction treatment policy.”

    The Honorable Paul Tonko

    U.S. Representative, NY 20th District


    2014 Media Award

    “To recognize achievement in the media providing a scientific, comprehensive, unflinching and compassionate look at addiction, and its effects on families and society as a whole.”

    Greg Williams, MA


    ASAM Annual Award

    “For outstanding contributions to the growth and vitality of our Society, for thoughtful leadership in the field, and for deep understanding of the art and science of Addiction Medicine .”

    Edwin A. Salsitz, MD, DFASAM


    Young Investigator Award

    “For the best abstract submitted by an author who is within five years receipt of a doctoral degree.”

    Shonali Saha, MD


    Medical-Scientific Program Committee Award- Best Paper

    “For the abstract receiving the highest rating for its scientific merit.”

    Kathleen Decker, MD


    ASAM/Millennium Labs Medical-Scientific Program Committee Award

    “To recognize and provide financial support for research efforts by Addiction Medicine Fellows (Restriction: 2-year residencies, only) and to encourage Fellows to understand and research medication monitoring and drug testing in the early phases of their careers in the field of addiction medicine.”

    Kenneth Blum, PhD


    ASAM/Millennium Research Fellowship Research Award

    “To recognize and provide financial support for research efforts by Addiction Medicine Fellows and to encourage Fellows to understand and research medication monitoring and drug testing in the early phases of their careers in the field of addiction medicine.”

    Sarah Bagley, MD



    Tickets for the Awards Luncheon are available for $75 per person. Please visit the Registration Desk to sign up for this event.


    2:00 pm – 4:30 pm

    Exhibit Hall Reopens

    Exhibits officially close at 4:30 pm for the 2014 Med-Sci Conference

    Orlando Ballroom I-II, Lower Level

    2:00 pm – 4:00 pm

    Symposium 6B

    Development Biologics to Treat Substance Use Disorders: An Update for Clinicians – Part II

    Ivan Montoya, MD, MPH; Bridget Ann Martell, MD, MA; Paul Pentel, MD; Chang-Guo Zhan, PhD; W. Brooks Gentry, MD; Frank Orson, MD; Thomas Kosten, MD

    Sponsored by: National Institute on Drug Abuse (NIDA)

    Orange Ballroom D, Lower Level

    Substance Use Disorders (SUDs) are complex medical conditions that require multiple treatment approaches. To date, several biologics have been investigated and some of them have been tested in clinical trials, although none has met the efficacy endpoints required by the FDA for approval. New and improved biologics using new technologies offer opportunities to advance their discovery and development to treat SUDs. They include new ways to produce vaccines using nanotechnology, highly efficient engineered enzymes that metabolize cocaine orders of magnitude faster than then natural butyrylcholinesterase, and new ways to produce long acting antibodies. It is expected that at the end of the symposium the participants will have a better understanding of mechanisms of action of biologics to treat SUDS as well as their potential applications in clinical practice.

    Note: Attendance is encouraged at both Part I and Part II of this two-part Course in order to benefit from both the theoretical and clinical practice aspects of the material presented.



    Symposium 7

    Prescription Stimulant Use and Misuse Among Youth: Review and Practice Implications

    Amelia Arria, PhD; Paula Riggs, MD; Geetha Subramaniam, MD, FAPA; Norman Wetterau, MD, DFASAM; Timothy Wilens, MD

    Sponsored by: National Institute on Drug Abuse (NIDA)

    Orange Ballroom A, Lower Level

    Prescription stimulant medications are among the most effective treatments for youth with Attention Deficit Hyperactivity Disorder(ADHD). However, in the US, as prescriptions for stimulant medications for the treatment of ADHD have soared, so have their rates of misuse among youth, especially college students. The objectives of this symposium are to provide a comprehensive review of both the benefits of stimulants in ADHD and the related risks of this treatment modality. In the first half, three presenters will cover: a) the epidemiology and risk factors associated with prescription stimulant abuse in teens and college-age students; b) pharmacology/ efficacy evidence of stimulants for the treatment of ADHD in youth/young adults in addition to potential risks and negative consequences; and c) the utility of stimulant medication for substance abusing ADHD populations and clinical strategies to prevent and minimize diversion and misuse. In the interactive learning component that follows the symposium, chairs will lead case-based clinical discussions including (but not limited to): How to maximize medication adherence? How to determine high risk patients? How to identify those who may be feigning ADHD to score meds? And other ow-to questions you have for the expert panel.



    Course 4

    Core Knowledge Regarding Twelve-Step Modalities Important for the Addiction Medicine Physician

    Kenneth Thompson, MD, DFASAM; Scott Teitelbaum, MD, FAAP, DFASAM

    Orange Ballroom B, Lower Level

    Designed to provide the essential core knowledge regarding Alcoholics Anonymous (AA) and Twelve-Step interventions for the physicians who are caring for patients with substance use disorders, this course will demonstrate how to incorporate these important elements into the care of their substance using patients. It will be of particular interest to those who have not had a broad addiction background or experience in the use of Twelve-Step modalities. It will illustrate how Twelve-Step interventions are valuable and effective in the treatment of addiction as defined by ASAM. It will expand the understanding of Twelve-Step interventions as more than just the attendance of AA meetings and discuss the basic elements including meetings, step work, fellowship and sponsorship. Current scientific literature regarding Twelve-Step interventions will be reviewed. It will also address the use of Twelve-Step modalities in conjunction with the person on Medication Assisted treatment. Methods to incorporate Twelve-Step modalities into a practice style that has not previously emphasized Twelve-Step components will be provided and ways to overcome both patient and physician obstacles will be discussed. Case examples will be judiciously used to help illustrate the above topics.



    Workshop 4

    Updates in Treating Sedative Dependency In Addiction And Chronic Pain

    Mark Weiner, MD; Herbert Malinoff, MD, FACP, DFASAM; Melvin Pohl, MD, DFASAM

    Orange Ballroom C, Lower Level

    Sedatives in addiction in chronic pain patients present hazards to both recovery in the individual and to the treatment/management of chronic pain. The long term use of sedatives has been linked to cognitive and visual-spatial impairment, as well as worsening mood and a well-described "downward spiral" of worsening pain perception and dysfunction. Patients with chemical dependency are at higher risk for relapse when sedatives are prescribed. Therefore, the use of sedatives can destabilize even a robust recovery program. The purpose of this workshop is to assist practitioners in identifying if and when sedatives become problematic in their patients and to assist practitioners in the appropriate treatment strategies for withdrawal from sedatives. Primary care physicians, pain specialists and addiction specialists will become more familiar with benzodiazepines and benzodiazepine-like substances in order to identify problematic sedative use, unintended consequences of sedative use, and to appropriately withdraw patients from chronic sedative medications. Additionally, the rehabilitative care of patients once sedatives are withdrawn will be discussed.



    Workshop 5

    A Multidisciplinary Approach for Opioid Dependent Mothers and Their Infants

    Sarah Bagley, MD; Michelle Sia, DO; Kelley Saia, MD, BSN; Carrie Schultz, MSW

    Orlando Ballroom V, Lower Level

    The number of opiate dependent pregnant women has increased more than four-fold between 2000-2009, with an estimated 3.39 per 1000 infants born exposed to opiates in 2009 (or more than one infant born per hour in the US in 2009). Concurrent treatment of opiate addiction in the setting of prenatal care is critical for both the health of the mother and the fetus. Once the infant is born, coordination of obstetric, pediatric and addiction care can be challenging. The objective of this workshop is to provide best practices in addiction treatment for opioid dependent women, both prenatally and after delivery using the evidence-base and consensus. To achieve the objective, topics addressed will include opioid agonists for peri-partum women, support of the mother-infant dyad through the neonatal period, coordination of obstetric and pediatric care for mother-infant dyads, and leveraging the skills of the multidisciplinary team to optimize patient outcomes. The presenters will draw upon their rich clinical experiences including; running an obstetric clinic that caters to pregnant women with substance abuse, caring for women with substance abuse post-partum in primary care and support of the mother-infant dyad from a pediatric perspective.



    Workshop 6

    Virtual Consulting and Education in Pain and Addiction

    Ilene Robeck, MD; Christopher Spevak, MD, MPH, JD

    Orlando Ballroom IV, Lower Level

    The number of content matter experts in the fields of chronic pain and addiction are far fewer than is needed to address the current crisis in the United States. Innovations in consulting and education are important in order to provide the proper care for patients and teach other medical professionals the necessary skills. The need is especially great for consultation and education in primary care. This workshop will explore a number of new technological innovations and resources available to medical professionals that can assist in virtual consulting and education including: e-consulting, VA SCAN-ECHO consulting, clinical video tele-consulting, virtual team meetings, and apps. Following a formal didactic presentation on these innovations there will be case-based discussion about each of these innovations and how they can change patient care and provider education. This workshop will supply participants with strategies for caring for patients with pain and addiction problems even if virtual modalities are not readily available.


    4:00 pm – 4:30 pm

    (New) Ice Cream Novelties and Networking Reception in the Exhibit Hall

    Last chance to see Exhibitors

    Orlando Ballroom I-II, Lower Level

    Enjoy this last opportunity to visit with exhibitors while sampling a scrumptious selection of ice cream novelties. It’s a new twist on the “ice cream social.” Over a hundred exhibitors await you in ASAM’s state-of-the-art Exhibit Hall. Don’t miss this new Med-Sci featured event.


    4:30 pm



    4:30 pm – 6:00 pm

    2014 Exhibit Hall Closes

    Orlando Ballroom I-II, Lower Level


    Quality Improvement Council

    Lake Hart A, Lobby Level


    4:30 pm – 6:30 pm

    Symposium 8

    Evidence-Based Approaches to Alcohol Detoxification and Treatment

    Michael Fingerhood, MD, FACP; Darius Rastegar, MD; Kenneth B. Stoller, MD

    Orange Ballroom A, Lower Level

    Alcohol withdrawal syndrome is a potentially life-threatening condition. We will review the indications for pharmacologic treatment of withdrawal and the expanding literature on the effectiveness of pharmacologic agents, comparing the effectiveness of different benzodiazepines, as well as non-benzodiazepine agents including carbamazepine, baclofen, clonidine and beta-blockers. The second part of the session will focus on evidence based treatment for alcohol use disorders. The literature related to the use of pharmacologic agents for alcohol use disorder will be reviewed, focusing on disulfiram, naltrexone and acamprosate.



    Symposium 9

    CFR42.2 and the EMR: Necessary Protection or Barrier to Coordinated Care?

    Gavin Bart, MD, PhD, FACP, DFASAM; H. Westley Clark, MD, JD, MPH, DFASAM; Eric Goplerud, PhD, MA

    Orange Ballroom D, Lower Level

    This symposium will highlight the tension between privacy protection and coordinated addiction care in the era of the electronic medical record. In 1973, Title 42 of the Federal Code of Regulations (CFR 42.2) was amended to include confidentiality protections for alcohol and drug abuse patient records. The purpose of this was to assure that patients seeking help for substance use disorders in federally-assisted settings not be made more vulnerable by availability of the medical records related to their care than people who do not seek such help or who seek help in non-federally-assisted settings. Forty years later, the provision of addiction care has greatly transformed from almost purely stand-alone behavioral entities into an integrated component of large health care systems. In 2014, some now view CFR 42.2 as a barrier to coordinated care while others fear that the wide accessibility of electronic medical records makes CFR 42.2 all the more important. This tension is evident in a recent survey of addiction care providers 85% of whom indicated that CFR 42.2 was a barrier to integrated care while 35% thought it did not provide enough protection.

    Sponsored by: Substance Abuse and Mental Health Services Administration (SAMHSA)


    Course 5

    Neonatal Abstinence Syndrome: Understanding the Variations in Expression of Symptoms and Mitigating Them

    Karol Kaltenbach, PhD; Jack McCarthy, MD; Loretta Finnegan, MD, LLD (Hon), ScD (Hon)

    Orange Ballroom B, Lower Level

    National and international data demonstrate that an epidemic of opioid abuse, especially related to prescription drug dependence has caused a significant increase in the number of newborns experiencing Neonatal Abstinence Syndrome (NAS). The severity of NAS in newborn infants and the economic and emotional burden of NAS to hospitals and medical staff have been reported, however, there is almost no attention given to known strategies and current research to reduce the risks of NAS. Presented in a structured lecture format, this course will review basic concepts concerning the clinical picture, assessment, and treatment of neonatal abstinence syndrome (NAS). New data on methods to mitigate neonatal abstinence symptoms utilizing specialized but basic clinical techniques during pregnancy and in the neonatal period will also be presented. A better understanding of how to decrease NAS severity will assist nurses and physicians in newborn units and also may help to reduce biases against the use of agonist treatment in pregnancy, in addition to reducing morbidity for the baby.



    Collaborative Workshop

    Association for Medical Education and Research in Substance Abuse (AMERSA) – Addressing the Opioid Addiction and Overdose Epidemic: Targeting the Prescriber

    Alexander Y. Walley, MD; Hillary Kunins, MD, MPH, MS; Daniel P. Alford, MD, MPH, FACP, DFASAM

    Orlando Ballroom IV, Lower Level

    A new wave of opioid addiction and overdose since the 1990s has been intertwined with increased prescribing of prescription opioids for pain. Education about balancing the risks and benefits of opioid pain medication is one of the key strategies in addressing increasing opioid addiction and overdose promoted by public health. In this workshop, we will describe three approaches to educating prescribers to lower the risks of opioid addiction and overdose amongst their patients. Dr. Alford will describe universal prescriber education offered through the FDA’s Risk Evaluation and Mitigation Strategy (REMS) for Extended-Release and Long-Acting Opioids and mandated by the Massachusetts Board of Registration of Medicine. Dr. Kunins will describe targeted prescriber education efforts at the Bureau of Alcohol and Drug Use, New York City Department of Health and Mental Hygiene. Dr. Walley will describe how to integrate patient overdose education and naloxone rescue kits into prescriber-patient encounters. The session will conclude with a discussion about the impact and utility of these prescriber education efforts on clinical practice. This is a new workshop – faculty members are each AMERSA executive committee members involved in educating prescribers how to reduce the risks addiction and overdose.



    Paper Sessions – Group III

    Orange Ballroom C, Lower Level


    Session 1 – Quality of Life in Nicotine Addiction

    Matthew Goldenberg, DO; Itai Danovitch, MD; Waguih William IsHak, MD, FAPA

    Session 2 – Long-Term Outcome After Residential Substance Use Treatment

    Kathleen Decker, MD

    Session 3 – Psychological Pain in Substance Abuse: An Exploratory Study

    Steven Mee, MD

    Session 4 – Does Comorbid Alcohol Dependence Influence the Response Rates in Unipolar Depression Treatment?

    Senthil Vel Rajan, MD



    Component Session 13

    ABAM Certification 101

    Barbara Herbert, MD; Michael Weaver, MD, DFASAM; Martha J. Wunsch, MD, FAAP, DFASAM; Kevin Kunz, MD, MPH, DFASAM; Terri Silver, MA

    Orlando Ballroom V, Lower Level

    Addiction affects 40 million Americans - more than heart disease, diabetes or cancer. Another 80 million Americans use tobacco, alcohol, and other drugs that threaten their health. Many physicians don’t view themselves as practitioners in the field of addiction medicine, even though regardless of medical specialty, all physicians have patients with or at risk for substance use disorders. Certification by ABAM represents the highest standard in the addiction medicine field. Certified physicians have the clinical knowledge, experience and training necessary to recognize symptoms early, practice prevention and provide treatment. Session attendees will learn first-hand about the eligibility criteria and application process for the ABAM certification examination on November 15, 2014. Through an interactive question-and-answer session with current ABAM Diplomates, attendees will hear how certification has enhanced patient care and careers, set a standard for excellence in the addiction medicine field, and made a positive difference in the lives of your patients and their loved ones.


    5:00 pm – 6:00 pm

    Ruth Fox Endowment Scholarship Meeting

    Lake Hart B, Lobby Level



    5:30 pm – 6:30 pm

    Primary Care Interest Group Meeting

    Lake Florence A, Lobby Level

    5:30 pm – 6:30 pm

    Twelve Step Recovery Action Group Meeting

    Lake Florence B, Lobby Level

    8:00 pm – 9:30 pm

    ASAM Movie Night: “The Anonymous People”

    Orange Ballroom D, Lower Level

    ASAM is proud to present a special screening of “The Anonymous People,” a documentary film about the over 23 million Americans living in long-term recovery from alcohol and other drug addiction. ASAM 2014 Media Award winner, Greg Williams, MA, writer and producer/director of the film, will make a short introduction and field questions/comments after the screening.

    “The Anonymous People” explores the dilemma faced by those suffering from substance use disorders as well as those who treat them. Deeply entrenched social stigma has kept recovery voices silent and faces hidden for decades. The vacuum has been filled with sensational mass media depictions of people with addiction that perpetuate a lurid fascination with the dysfunctional side of what is a preventable and treatable health condition. Just like women with breast cancer, or people with HIV/AIDS, a grassroots social justice movement is emerging. Courageous addiction recovery advocates have come out of the shadows and are organizing to end discrimination and move toward recovery-based solutions.

    Enjoy the film and the lively discussion to follow.

    10:00 pm – 11:00 pm

    Mutual Help Meeting

    Lake Lucerne, Lobby Level

  • Sunday, April 13, 2014


    7:00 am – 8:00 am

    Mutual Help Meeting

    Lake Lucerne, Lobby Level

    7:00 am – 12:00 pm

    Registration Open

    Orlando Ballroom Foyer, Lower Level

    7:00 am – 8:00 am

    Continental Breakfast in the Foyer

    Orange Ballroom Foyer, Lower Level

    8:00 am – 10:00 am

    Symposium 10

    Introduction to Building Skills in Motivational Interviewing * (Limited to first 32 Attendees)

    Judith Martin, MD, DFASAM; Sharone Abramowitz, MD; Paula Lum, MD, MPH; Paul Seale, MD; Karena Franses, MSW, LCSW

    Orange Ballroom C, Lower Level

    Motivational Interviewing is defined by the Substance Abuse and Mental Health Services Agency (SAMHSA) as, “a collaborative, person-centered form of guiding to elicit and strengthen motivation for change. It is an empathic, supportive counseling style that supports the conditions for change. Practitioners are careful to avoid arguments and confrontation, which tend to increase a person's defensiveness and resistance. Motivational interviewing is a proven and effective way to engage individuals with co-occurring disorders, develop therapeutic relationships, and determine individualized goals. Research shows that motivational interviewing techniques, including counseling, assessment, multiple sessions, and brief interventions, are associated with greater participation in treatment and positive treatment outcomes. ” Whether you are new to addiction medicine, or have been in the field for years you can always improve your communication with patients as you help them change their behavior. In this symposium leaders in SBIRT and Motivational Interviewing will guide participants in practice of screening and basic MI skills, with feedback in small groups.


    * This highly interactive session will not be recorded and will not be available online through ASAM's e-LLC after the conference.



    Symposium 11

    Marijuana: Addiction Physicians and the American Public 2014

    Andrea Barthwell, MD, DFASAM; Gregory C. Bunt, MD; Stuart Gitlow, MD, MPH, MBA, FAPA; Jag Khalsa, PhD, MS; Sharon Stancliff, MD; Norman Wetterau, MD, FAAP, DFASAM

    Orange Ballroom D, Lower Level

    Given the recent developments in legislation and public perception about legalizing medical marijuana and recreational marijuana, ASAM physicians are now faced with unprecedented challenges in clinical practice, advocacy and public education. Common questions that arise include: Are ASAM physicians in favor of decriminalization of marijuana? How is the decriminalization of marijuana defined? What should be the role of law enforcement with marijuana users? How harmful is marijuana - as an addictive substance; as a toxic substance; as a gateway drug? Can ASAM Physicians currently influence the increase in marijuana access and abuse, and if so how? How do ASAM physicians regard the potential therapeutic benefits of Cannabidiol, and/or other cannabinoids? What specific ASAM policies should be established regarding marijuana? Marijuana, like alcohol is being commercialized and promoted with huge profits how should ASAM respond to this? The commercial promotion of marijuana includes comparison with alcohol, implying that marijuana would be a safer and better recreational drug for the nation than alcohol how do ASAM physicians respond? What lessons can be learned internationally from countries abroad such as Holland and Portugal? These questions will be posed to a distinguished panel of experts for discussion and debate, with vigorous audience participation.



    Workshop 7

    Lifelong Learning: Review of articles for ABAM MOC Part 2

    Michael Weaver, MD, DFASAM; Lia Bennett, MPH; Michael Fingerhood, MD, FACP; Alex Walley, MD

    Orange Ballroom A, Lower Level

    In an effort to raise the standard of medical care provided by ABAM Diplomates, this workshop will guide participants through the steps of completing the ABAM Maintenance of Certification(MOC) Part II: Lifelong Learning and Self-Assessment. There will be an interactive demonstration of the new ABAM Online Diplomate Portal which allows those participating in MOC to access articles and respond to questions. Presenters will also discuss techniques and guidelines for reviewing and critiquing articles in a clinically meaningful way. Presenters will use recent articles in addiction medicine, that have already been selected for MOC Part II, to illustrate the review process and educate participants on the latest research findings in addiction medicine, including how this impacts patient care. Participants will be able to create clinical questions of their own that can be used to begin a search of the medical literature. There will be ample opportunity for participants to ask questions and provide comments.



    Paper Sessions – Group IV

    Orange Ballroom B, Lower Level


    Session 1 – Increase in Opioid Dependent Admissions and Atypical Discharges in Residential Treatment

    Pamela Shultz, MD; Marvin Seppala, MD; Justin Anker, MD

    Session 2 – Opioid Addiction and Mental Health: Evaluating a Model of Care for Youth

    Kim Corace, PhD; Melanie Willows, MD, BSc, CCFP, CASAM, CCSAM

    Session 3 – Buprenorphine/Naloxone Buccal Film is Well Tolerated in Opioid - Dependent Patients Converted from Suboxone

    Kent S. Hoffman, DO

    Session 4 – Factors Affecting Treatment Outcomes in Elderly Illicit Drug Users: A Case Series

    Padmapriya Musunuri, MBBS, MRC; Gibson George, MBBS; Carolina Retamero, MD; Marc Zisselman, MD

    Session 5 – The Extended-Release Naltrexone (XR-NTX) Opioid Dependence Registry: Clinical and Functional Effectiveness

    Frank Vocci, PhD


    10:00 am – 10:15 am

    Refreshment Break in the Foyer

    Orange Ballroom Foyer, Lower Level

    10:15 am – 12:15 pm

    Symposium 12

    Interdisciplinary Models in Training the Next Generation of Addiction Professionals

    Lauren Broyles, PhD; Adam Gordon, MD, MPH, DFASAM

    Orange Ballroom A, Lower Level

    The Institute of Medicine recognizes that patients with alcohol and other drug (AOD) use do not routinely receive high quality care from healthcare providers and would benefit from comprehensive, interdisciplinary approaches. A new paradigm of integration and coordination of healthcare services is emerging to more comprehensively address the spectrum of AOD use and AOD disorders. The NIH Roadmap calls for interdisciplinary research teams of the future that blend theoretical orientations, methodologies, perspectives, and resources across disciplines to address increasingly complex scientific questions. Clinicians, clinical-educators, and clinical-investigators do not typically receive formal skills training or practice in communicating, collaborating, and overcoming logistical or institutional barriers to working effectively with professionals who are socialized into other disciplines and perspectives. A new paradigm is needed to teach the next generation of addiction professionals in clinical practice, clinical-education, and clinical research. In this symposium, we will explore the different models of training of addiction. We will focus on describing and comparing the modalities of training the next generation of addiction professionals, educators, and researchers on health care professional student, post-graduate, and continuing medical education levels. An interdisciplinary education approach to teaching will be advocated and models of training will be discussed.



    Symposium 13

    Medication vs. Non-Medication Approaches to Recovery

    Petros Levounis, MD, MA, DFASAM; Charlie Morgan, MD, FAAFP, DFASAM; Mel Pohl, MD, DFASAM; Sharon Stancliff, MD; Kenneth Thompson, MD, DFASAM

    Orange Ballroom D, Lower Level

    The debate continues over non-medication versus medication-assisted treatment of addiction from the perspective of patients who have chosen different ways of addressing the addictive process. We will review both research data and clinical experience with diverse treatment methodologies that may or may not be mutually exclusive. We will explore the polar extremes, as well as the in-between approaches, in the medication versus non-medication orientation spectrum of treatment. Dr. Ken Thompson will present treatment options based on non-medication, abstinence, and spiritual principles, while Dr. Sharon Stancliff will present the medication-assisted approach. Dr. Levounis will discuss the concept of recovery as defined in mental health treatment systems and contrast it with recovery as understood in addiction treatment. Dr. Mel Pohl will share his experience with non-medication addiction treatment work. Expect lively discussion about this on-going debate within the addiction treatment community.



    Course 6

    Evaluation and Treatment of Substance Use Disorders in Active Duty Military

    Anthony Dekker, DO, DFASAM; Donald Berghman, MD; Chideha Ohuoha, MD, MPH; George Ceremuga, DO

    Orange Ballroom B, Lower Level

    Evaluation and Treatment of Active Duty Service Members has challenged many civilian programs. The relapse rates often exceed 80% at one year. The military interventions at the Fort Belvoir Community Hospital have utilized special treatments that have improved the treatment success rates to nearly 80% with tight criteria for measurements. All issues are addressed and treatment teams coordinate interventions utilizing a military model. Complementary and integrative methods are integrated into the programs. Chronic pain disorders are addressed with a multidisciplinary approach including Medication Assisted Therapies (MAT). Providers will be expected to understand the medical and psychiatric co-morbidities commonly seen in military members with substance use disorders. Basic appreciation of of intervention strategies with Cognitive Behavioral Therapies, Dialectical Behavioral Therapies, Integrative and Complementary interventions for behavioral, physical, and spiritual issues. The use of the multidisciplinary and transdisciplinary systems are emphasized in this program.



    Course 7

    Work-up and Treatment of the Opioid-Addicted Pain Patient; Ground-Zero, Florida

    Nancy Lee Kopitnik, DO, JD

    Orange Ballroom C, Lower Level

    The State of Florida requirement for risk assessment has necessitated the development of an effective model for the initial stratification of high risk pain patients with opiate use disorders. This presentation will discuss how our model allows inclusion of a variety of patients rather than exclusion and how such a model for stratification of a variety of patients--from low risk pain patients, who are opiate naïve; to patients with behavioral problems, who are opioid dependent; pain patients with high-dose opioid requirements. Topics will include: the triage of impaired professionals; how to individualize work-ups and the formulation of individualized treatment plans; a model of the addiction/pain initial history and physical examination, behavioral examination and testing; and ultimately the practicality of setting this up in the physician's office. Finally, the presentation will discuss how the development of the model used, to meet a regulatory need in the State of Florida, helped identify greater numbers of persons with both pain and addiction issues, who were lacking both information and treatment sources.


    12:15 pm

    Official Closing of ASAM's 45th Annual Medical-Scientific Conference.

    See You in Austin, TX, April 23-26, 2015